2022 Pathway to Stop Diabetes - Initiator Award (INI) or Accelerator Awards (ACC)

M. Dodson

UArizona is allowed a maximum of one nomination per grant cycle to one of the Pathway Program Award types: Initiator or Accelerator. Institutions may not submit nominations in multiple award types in a single grant cycle.

To accelerate the research needed to stop this deadly disease, the American Diabetes Association’s bold transformational initiative, Pathway to Stop Diabetes, is inspiring a new generation of diabetes researchers.

Eligibility for Accelerator Awards (ACC)
Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for (regardless of outcome), or received, an R01/U01 renewal or a second R01/U01 award. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.

Amount Upper: $1,625,000USD
Award Term: Up to 5 years
Maximum Funding: $325,000/year

Eligibility for Initiator Award (INI)
Eligible applicants must currently be in research training positions (post-doctoral fellow, research fellowship) and have no more than seven years of research training following terminal doctoral degree. Applicants cannot concurrently hold an NIH K99/R00 grant. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.

Amount Upper: $1,625,000USD
Award Term: Up to 7 year
Maximum Funding: Up to $100,000/year in Phase 1, Up to $325,000/year in Phase 2